Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia.

Still, the overall week 12 Gocovri-related treatment-difference relative to placebo in MDS-UPDRS Part I (−0.8) did not reach statistical significance relative to placebo ( P = 0.22), perhaps owing to offsetting effects of opposite directional change for some scale items, combined with the fact that meaningful presence of NMS was not a requirement for study entry, thereby limiting the ability to fully evaluate potential for change in many symptoms.

also in 111,027 other papers

On item analysis, daytime sleepiness and depression showed significant improvement relative to placebo at 12 weeks, and pain showed a positive trend but did not reach significance.

also in 11,005 other papers